Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions


Pharmaceutical Technology



Figure 1
The most important feature in terms of local mixing is the dynamic behavior of the droplet (or bubble) wake, which has been extensively studied (24–25). Studies of wake phenomena and fluid flow past solid obstacles date as far back as Leonardo da Vinci (26). Subsequent studies focused on the development of highly accurate pendulum clocks for the determination of a ship's location at high sea. The construction of these clocks required a detailed understanding of the airflow and drag around a swinging pendulum (The Longitude Act was passed in England in 1714, in which Parliament promised a prize of 20,000 pounds for the solution of the "longitude problem." To win the prize, the inventor had to construct an accurate and reliable pendulum clock, requiring a precise understanding of the wake behind the pendulum) (27).


Notations
The wake behind droplets and bubbles consists of a primary wake moving in close association with the droplet and a secondary wake extending far downstream (28). Typically three different wake types are observed: a steady-wake without circulation (see Figure 1a), a steady wake with a well-developed circulation zone that can grow significantly (see Figure 1b), and an unsteady wake with vortical structures and vortex shedding (see Figure 1c) (22, 25, 28–33).

Clearly the mixing in these wakes is very different. For example, Figure 2 shows the contour plots of dissolving gas from a bubble rising with the three different wake types. It can be seen that in the case of the steady wake, the gas is concentrated in a small region behind the bubble (see Figures 2a and 2b). In the case of vortex shedding, the gas is rapidly dispersed into the liquid phase (see Figure 2c). It is obvious that in the case of fast, mixing-sensitive reactions, these different types of wakes will result in different product distributions. In an article published in 2000, the authors addressed this problem by analyzing computationally this phenomenon for a fast parallel-consecutive reaction network:












ADVERTISEMENT

RELATED CONTENT
Roche Recalls Viracept
Copolymerized PEGlyated Acrylate Hydrogels for Delivery of Dicolofenac Sodium
The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
Near-Infrared Assay and Content Uniformity of Tablets
Maintain Your Moving Parts
blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here